ICON Public Limited (NASDAQ:ICLR) Receives $289.10 Average Target Price from Analysts

ICON Public Limited (NASDAQ:ICLR) has been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $289.10.

Several research analysts have issued reports on ICLR shares. TD Cowen dropped their target price on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Baird R W lowered shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. Redburn Atlantic initiated coverage on shares of ICON Public in a research note on Monday, October 14th. They set a “neutral” rating and a $311.00 price target on the stock. Finally, Barclays reduced their price objective on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research note on Friday, October 25th.

ICON Public Price Performance

ICLR opened at $213.28 on Thursday. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The stock has a 50-day moving average price of $212.09 and a 200-day moving average price of $275.20. The firm has a market cap of $17.59 billion, a PE ratio of 23.78, a P/E/G ratio of 1.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.10 EPS. Sell-side analysts predict that ICON Public will post 13.42 earnings per share for the current fiscal year.

Institutional Trading of ICON Public

Institutional investors and hedge funds have recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC acquired a new position in shares of ICON Public during the second quarter worth $54,000. EverSource Wealth Advisors LLC increased its holdings in shares of ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 111 shares during the last quarter. GAMMA Investing LLC raised its position in shares of ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after purchasing an additional 96 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares in the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.